Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.72 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908570 | 1.00 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL14681244 | 1.00 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL19174157 | 1.00 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL29397407 | 1.00 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL1044067 | 0.90 | CYP4F2 (0.61) | CYP4F2CYP4A11ALDH1A1TDP1POLB | |
| SCHEMBL915319 | 0.87 | CYP4F2 (0.56) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL13230299 | 0.87 | CYP4F2 (0.75) | CYP4F2CYP4A11CHRM1ALDH1A1POLB | |
| SCHEMBL10508228 | 0.86 | CYP4F2 (0.73) | CYP4F2CYP4A11ALDH1A1POLBKMT2A | |
| SCHEMBL3911095 | 0.85 | CYP4F2 (0.54) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL13762677 | 0.85 | CYP4F2 (0.52) | CYP4F2CYP4A11MLNRADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110791488-A | Lipase for splitting chiral compound and preparation method and application thereof | 西南交通大学 | 2020-02-14 | — | — | CN | claimed |
| CN-114149956-B | Escherichia coli genetically engineered bacterium for expressing esterase EstR and application thereof | 华东理工大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-114214261-B | Escherichia coli genetically engineered bacterium for expressing esterase EstS and application thereof | 华东理工大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-114150036-B | Continuous biphasic batch resolution process for preparing optically pure 6-fluoro-chroman-2-carboxylic acid | 华东理工大学 | 2024-01-09 | — | — | CN | disclosed |
| EP-3974419-A2 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| CN-114214261-A | Escherichia coli genetic engineering bacterium for expressing esterase EstS and application thereof | 华东理工大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-114150036-A | Continuous two-phase batch resolution process for preparing optically pure 6-fluoro-chroman-2-carboxylic acid | 华东理工大学 | 2022-03-08 | — | — | CN | disclosed |
| CN-114149956-A | Escherichia coli genetic engineering bacterium for expressing esterase EstR and application thereof | 华东理工大学 | 2022-03-08 | — | — | CN | disclosed |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-02-24 | — | — | US | disclosed |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1332133-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008040528-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008010022-A2 | A PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (US) | 2008-01-24 | — | — | WO | disclosed |
| US-7115630-B2 | Metabotropic glutamate receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-03 | — | — | US | disclosed |
| US-20060083676-A1 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTIA N.V. (BE) | 2006-04-20 | — | — | US | disclosed |
| US-20040082592-A1 | Metabotropic glutamate receptor antagonists | JANSSEN-CILAG SA (FR) | 2004-04-29 | — | — | US | disclosed |
| EP-0145067-B1 | DERIVATIVES OF 2,2'-IMINOBISETHANOL | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-25 | — | — | EP | disclosed |
| US-4654362-A | CARDIOVASCULAR DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1987-03-31 | — | — | US | disclosed |
| EP-0145067-A2 | Derivatives of 2,2'-iminobisethanol | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082592-A1 | Metabotropic glutamate receptor antagonists | GRM3, GRM1, GRIN3A | CYP4F2 716/4885CYP4A11 369/4885MLNR 1058/4885 |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | ADRB1, ADRB2, ADRA2B | CYP4F2 258/4885CYP4A11 35/4885MLNR 452/4885 |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | CYP4A11, CYP11B2, ADRB1 | CYP4F2 122/4885CYP4A11 1/4885MLNR 2189/4885 |
| US-20060083676-A1 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | GRM3, GRM1, GRM2 | CYP4F2 260/4885CYP4A11 511/4885MLNR 984/4885 |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, CYP11B1 | CYP4F2 115/4885CYP4A11 1/4885MLNR 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.